环状RNA适配体靶向IGF2BP2以克服获得性BETi耐药性。 - Suppr

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

作者信息

Nicot Christophe

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

出版信息

Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.

DOI:10.1186/s12943-025-02423-6

PMID:40784877

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335760/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfd5/12335760/4fcc9cf514e0/12943_2025_2423_Fig1_HTML.jpg

相似文献

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.

A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.

Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.

Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.

Blood. 2020 Apr 9;135(15):1255-1269. doi: 10.1182/blood.2019002922.

Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.

Cancer Res. 2024 Apr 1;84(7):1101-1114. doi: 10.1158/0008-5472.CAN-23-0291.

Concurrent targeting of MAP3K3 and BRD4 by overcomes acquired resistance to BET inhibitors in neuroblastoma cells.

Mol Ther Nucleic Acids. 2021 May 11;25:83-92. doi: 10.1016/j.omtn.2021.05.001. eCollection 2021 Sep 3.

Circ_0000847 promotes the migration, invasion, and EMT process in colorectal cancer through binding to IGF2BP2 to enhance IGF2 mRNA stability.

Med Oncol. 2025 Aug 22;42(10):436. doi: 10.1007/s12032-025-02877-0.

circDHX33 suppresses glycolysis, malignant proliferation, and metastasis in prostate cancer by interacting with RNA-binding protein IGF2BP2 to destabilize its protein.

Cytotechnology. 2025 Apr;77(2):56. doi: 10.1007/s10616-025-00718-6. Epub 2025 Feb 6.

Circ_0006646 Promotes the Progression of Osteoarthritis via Upregulating CDH11 Expression in an IGF2BP2-Dependent Manner.

Kaohsiung J Med Sci. 2025 Aug;41(8):e70031. doi: 10.1002/kjm2.70031. Epub 2025 May 19.

Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.

J Cancer Res Clin Oncol. 2022 Apr;148(4):803-821. doi: 10.1007/s00432-021-03885-z. Epub 2022 Jan 30.

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.

Cancers (Basel). 2020 Jun 20;12(6):1637. doi: 10.3390/cancers12061637.

本文引用的文献

A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.

Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.

Signal Transduct Target Ther. 2023 Nov 6;8(1):420. doi: 10.1038/s41392-023-01647-6.

Why rings of RNA could be the next blockbuster drug.

Nature. 2023 Oct;622(7981):22-24. doi: 10.1038/d41586-023-03058-7.

BET proteins: Biological functions and therapeutic interventions.

Pharmacol Ther. 2023 Mar;243:108354. doi: 10.1016/j.pharmthera.2023.108354. Epub 2023 Feb 3.

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.

J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI133090.

Screening for functional circular RNAs using the CRISPR-Cas13 system.

Nat Methods. 2021 Jan;18(1):51-59. doi: 10.1038/s41592-020-01011-4. Epub 2020 Dec 7.

DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.

Mol Cell. 2018 Aug 16;71(4):592-605.e4. doi: 10.1016/j.molcel.2018.06.036. Epub 2018 Jul 26.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

作者信息

Nicot Christophe

机构信息

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

出版信息

Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.

DOI:10.1186/s12943-025-02423-6

PMID:40784877

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335760/

Abstract

摘要

相似文献

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

Mol Cancer. 2025 Aug 10;24(1):214. doi: 10.1186/s12943-025-02423-6.

A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.

Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.

Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.

Blood. 2020 Apr 9;135(15):1255-1269. doi: 10.1182/blood.2019002922.

Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.

Cancer Res. 2024 Apr 1;84(7):1101-1114. doi: 10.1158/0008-5472.CAN-23-0291.

Concurrent targeting of MAP3K3 and BRD4 by overcomes acquired resistance to BET inhibitors in neuroblastoma cells.

Mol Ther Nucleic Acids. 2021 May 11;25:83-92. doi: 10.1016/j.omtn.2021.05.001. eCollection 2021 Sep 3.

Circ_0000847 promotes the migration, invasion, and EMT process in colorectal cancer through binding to IGF2BP2 to enhance IGF2 mRNA stability.

Med Oncol. 2025 Aug 22;42(10):436. doi: 10.1007/s12032-025-02877-0.

circDHX33 suppresses glycolysis, malignant proliferation, and metastasis in prostate cancer by interacting with RNA-binding protein IGF2BP2 to destabilize its protein.

Cytotechnology. 2025 Apr;77(2):56. doi: 10.1007/s10616-025-00718-6. Epub 2025 Feb 6.

Circ_0006646 Promotes the Progression of Osteoarthritis via Upregulating CDH11 Expression in an IGF2BP2-Dependent Manner.

Kaohsiung J Med Sci. 2025 Aug;41(8):e70031. doi: 10.1002/kjm2.70031. Epub 2025 May 19.

Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.

J Cancer Res Clin Oncol. 2022 Apr;148(4):803-821. doi: 10.1007/s00432-021-03885-z. Epub 2022 Jan 30.

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.

Cancers (Basel). 2020 Jun 20;12(6):1637. doi: 10.3390/cancers12061637.

本文引用的文献

A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC.

Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2504320122. doi: 10.1073/pnas.2504320122. Epub 2025 Jul 1.

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.

Signal Transduct Target Ther. 2023 Nov 6;8(1):420. doi: 10.1038/s41392-023-01647-6.

Why rings of RNA could be the next blockbuster drug.

Nature. 2023 Oct;622(7981):22-24. doi: 10.1038/d41586-023-03058-7.

BET proteins: Biological functions and therapeutic interventions.

Pharmacol Ther. 2023 Mar;243:108354. doi: 10.1016/j.pharmthera.2023.108354. Epub 2023 Feb 3.

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.

J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI133090.

Screening for functional circular RNAs using the CRISPR-Cas13 system.

Nat Methods. 2021 Jan;18(1):51-59. doi: 10.1038/s41592-020-01011-4. Epub 2020 Dec 7.

DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.

Mol Cell. 2018 Aug 16;71(4):592-605.e4. doi: 10.1016/j.molcel.2018.06.036. Epub 2018 Jul 26.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14.

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance.

作者信息

机构信息

出版信息

相似文献

本文引用的文献